Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

The drug industry is facing one of the largest patent cliffs in recent history. Will that mean dealmaking at the annual J.P.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting them on course to position the drug across the spectrum of patients with ...

In August, CMS announced discounts on 10 popular drugs like Enbrel, Jardiance and Januvia, starting in 2026. In Q4 2024, Medicare Part B patients could save up to $3,000 on key cancer medications ...

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...

In each pair, one patient had received Jardiance, a pill from a class of drugs known as SGLT2 inhibitors, and the other received a DPP4 inhibitor such as Merck’s (MRK.N), opens new tab Januvia ...

The quest for effective weight loss solutions has never been more urgent, with millions of people worldwide struggling to ...

More than 110,000 North Carolinians are projected to benefit from a $2,000 annual cap on out-of-pocket costs for covered prescription drugs for Medicare Part D participants.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.